Patents by Inventor Jim Abraham
Jim Abraham has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20250125034Abstract: Comprehensive molecular profiling provides a wealth of data concerning the molecular status of patient samples. Such data can be compared to patient response to treatments to identify biomarker signatures that predict response or non-response to such treatments. This approach has been applied to identify biomarker signatures that strongly correlate with response of colorectal cancer patients to FOLFOX. Described herein are data structures, data processing, and machine learning models to predict effectiveness of a treatment for a disease or disorder of a subject having a particular set of biomarkers, as well as an exemplary application of such a model to precision medicine, e.g., to methods for selecting a treatment based on a molecular profile, e.g., a treatment comprising administration of 5-fluorouracil/leucovorin combined with oxaliplatin (FOLFOX) or with irinotecan (FOLFIRI).Type: ApplicationFiled: October 31, 2024Publication date: April 17, 2025Inventors: Jim Abraham, David Spetzler, Anthony Helmstetter, Wolfgang Michael Korn, Daniel Magee
-
Patent number: 12165759Abstract: Comprehensive molecular profiling provides a wealth of data concerning the molecular status of patient samples. Such data can be compared to patient response to treatments to identify biomarker signatures that predict response or non-response to such treatments. This approach has been applied to identify biomarker signatures that strongly correlate with response of colorectal cancer patients to FOLFOX. Described herein are data structures, data processing, and machine learning models to predict effectiveness of a treatment for a disease or disorder of a subject having a particular set of biomarkers, as well as an exemplary application of such a model to precision medicine, e.g., to methods for selecting a treatment based on a molecular profile, e.g., a treatment comprising administration of 5-fluorouracil/leucovorin combined with oxaliplatin (FOLFOX) or with irinotecan (FOLFIRI).Type: GrantFiled: April 22, 2022Date of Patent: December 10, 2024Assignee: Caris MPI, Inc.Inventors: Jim Abraham, David Spetzler, Anthony Helmstetter, Wolfgang Michael Korn, Daniel Magee
-
Publication number: 20240177821Abstract: Comprehensive molecular profiling provides a wealth of data concerning the molecular status of patient samples. Such data can be compared to patient response to treatments to identify biomarker signatures that predict response or non-response to such treatments. This approach has been applied to identify biomarker signatures that correlate with response of cancer patients to platinum-based chemotherapy. Described herein are data structures, data processing, and machine learning models to predict a probability of benefit of a treatment for a disease or disorder of a subject having a particular set of biomarkers, as well as an exemplary application of such a model to precision medicine, e.g., to methods for selecting a treatment based on a molecular profile, e.g., a treatment comprising platinum therapy.Type: ApplicationFiled: November 14, 2023Publication date: May 30, 2024Inventors: Jim Abraham, Wolfgang Michael Korn, David Spetzler
-
Publication number: 20240060139Abstract: Comprehensive molecular profiling provides a wealth of data concerning the molecular status of patient samples. Such data can be compared to patient response to treatments to identify biomarker signatures that predict response or non-response to such treatments. This approach has been applied to identify biomarker signatures that predict cancer patient benefit from PARP inhibitors.Type: ApplicationFiled: December 15, 2021Publication date: February 22, 2024Inventors: Jim Abraham, David Spetzler
-
Publication number: 20230416829Abstract: Comprehensive molecular profiling provides a wealth of data concerning the molecular status of patient samples. Such data can be compared to patient response to treatments to identify biomarker signatures that predict response or non-response to such treatments. This approach has been applied to identify biomarker signatures that predict cancer patient benefit from immunotherapy such as checkpoint inhibitor therapy.Type: ApplicationFiled: November 10, 2020Publication date: December 28, 2023Inventors: Jim Abraham, David Spetzler
-
Patent number: 11842805Abstract: Comprehensive molecular profiling provides a wealth of data concerning the molecular status of patient samples. Such data can be compared to patient response to treatments to identify biomarker signatures that predict response or non-response to such treatments. This approach has been applied to identify biomarker signatures that correlate with response of cancer patients to platinum-based chemotherapy. Described herein are data structures, data processing, and machine learning models to predict a probability of benefit of a treatment for a disease or disorder of a subject having a particular set of biomarkers, as well as an exemplary application of such a model to precision medicine, e.g., to methods for selecting a treatment based on a molecular profile, e.g., a treatment comprising platinum therapy.Type: GrantFiled: June 2, 2022Date of Patent: December 12, 2023Assignee: Caris MPI, Inc.Inventors: Jim Abraham, Wolfgang Michael Korn, David Spetzler
-
Publication number: 20230368915Abstract: Comprehensive molecular profiling provides a wealth of data concerning the molecular status of patient samples. Such data can be used to train machine learning models using disease outcomes to identify biomarker signatures that can provide a prediction of such outcomes. This approach has been applied to identify biomarker signatures and machine learning models that can predict metastatic potential.Type: ApplicationFiled: September 10, 2021Publication date: November 16, 2023Inventors: Jim Abraham, David Spetzler
-
Publication number: 20230178245Abstract: Comprehensive molecular profiling provides a wealth of data concerning the molecular status of patient samples. Such data can be compared to patient response to treatments to identify biomarker signatures that predict response or non-response to such treatments. This approach has been applied to identify biomarker signatures that predict cancer patient benefit from immunotherapy such as checkpoint inhibitor therapy.Type: ApplicationFiled: April 30, 2021Publication date: June 8, 2023Inventors: Jim Abraham, David Spetzler
-
Publication number: 20230113092Abstract: Comprehensive molecular profiling provides a wealth of data concerning the molecular status of patient samples. Such data can be compared to patient response to treatments to identify biomarker signatures that predict response or non-response to such treatments. Here, we used molecular profiling data to identify biomarker signatures (biosignatures) that predict a tumor primary lineage, cancer category or type, organ group and/or histology. The signature may use genomic and transcriptome level information.Type: ApplicationFiled: February 16, 2021Publication date: April 13, 2023Inventors: Jim Abraham, David Spetzler
-
Publication number: 20220319658Abstract: Comprehensive molecular profiling provides a wealth of data concerning the molecular status of patient samples. Such data can be compared to patient response to treatments to identify biomarker signatures that predict response or non-response to such treatments. This approach has been applied to identify biomarker signatures that correlate with response of cancer patients to platinum-based chemotherapy. Described herein are data structures, data processing, and machine learning models to predict a probability of benefit of a treatment for a disease or disorder of a subject having a particular set of biomarkers, as well as an exemplary application of such a model to precision medicine, e.g., to methods for selecting a treatment based on a molecular profile, e.g., a treatment comprising platinum therapy.Type: ApplicationFiled: June 2, 2022Publication date: October 6, 2022Inventors: Jim ABRAHAM, Wolfgang Michael KORN, David SPETZLER
-
Publication number: 20220262494Abstract: Comprehensive molecular profiling provides a wealth of data concerning the molecular status of patient samples. Such data can be compared to patient response to treatments to identify biomarker signatures that predict response or non-response to such treatments. This approach has been applied to identify biomarker signatures that strongly correlate with response of colorectal cancer patients to FOLFOX. Described herein are data structures, data processing, and machine learning models to predict effectiveness of a treatment for a disease or disorder of a subject having a particular set of biomarkers, as well as an exemplary application of such a model to precision medicine, e.g., to methods for selecting a treatment based on a molecular profile, e.g., a treatment comprising administration of 5-fluorouracil/leucovorin combined with oxaliplatin (FOLFOX) or with irinotecan (FOLFIRI).Type: ApplicationFiled: April 22, 2022Publication date: August 18, 2022Inventors: Jim ABRAHAM, David SPETZLER, Anthony HELMSTETTER, Wolfgang Michael KORN, Daniel MAGEE
-
Patent number: 11315673Abstract: Comprehensive molecular profiling provides a wealth of data concerning the molecular status of patient samples. Such data can be compared to patient response to treatments to identify biomarker signatures that predict response or non-response to such treatments. This approach has been applied to identify biomarker signatures that strongly correlate with response of colorectal cancer patients to FOLFOX. Described herein are data structures, data processing, and machine learning models to predict effectiveness of a treatment for a disease or disorder of a subject having a particular set of biomarkers, as well as an exemplary application of such a model to precision medicine, e.g., to methods for selecting a treatment based on a molecular profile, e.g., a treatment comprising administration of 5-fluorouracil/leucovorin combined with oxaliplatin (FOLFOX) or with irinotecan (FOLFIRI).Type: GrantFiled: May 28, 2021Date of Patent: April 26, 2022Assignee: Caris MPI, Inc.Inventors: Jim Abraham, David Spetzler, Anthony Helmstetter, Wolfgang Michael Korn, Daniel Magee
-
Publication number: 20220093217Abstract: Comprehensive molecular profiling provides a wealth of data concerning the molecular status of patient samples. Such data can be compared to patient response to treatments to identify biomarker signatures that predict response or non-response to such treatments. Here, we used molecular profiling data to identify biomarker signatures that predict a tumor primary lineage or organ group.Type: ApplicationFiled: January 8, 2020Publication date: March 24, 2022Inventors: Jim Abraham, David Spetzler, Wolfgang Michael Korn
-
Publication number: 20210295979Abstract: Comprehensive molecular profiling provides a wealth of data concerning the molecular status of patient samples. Such data can be compared to patient response to treatments to identify biomarker signatures that predict response or non-response to such treatments. This approach has been applied to identify biomarker signatures that strongly correlate with response of colorectal cancer patients to FOLFOX. Described herein are data structures, data processing, and machine learning models to predict effectiveness of a treatment for a disease or disorder of a subject having a particular set of biomarkers, as well as an exemplary application of such a model to precision medicine, e.g., to methods for selecting a treatment based on a molecular profile, e.g., a treatment comprising administration of 5-fluorouracil/leucovorin combined with oxaliplatin (FOLFOX) or with irinotecan (FOLFIRI).Type: ApplicationFiled: May 28, 2021Publication date: September 23, 2021Applicant: CARIS MPI, INC.Inventors: Jim Abraham, David Spetzler, Anthony Helmstetter, Wolfgang Michael Korn, Daniel Magee